Publication | Closed Access
157 Overall survival advantage for pegylated liposomal doxorubicin compared to topotecan in recurrent epithelial ovarian cancer
12
Citations
0
References
2003
Year
MedicineMetronomic TherapyPathologyCancer Cell BiologyGynecologyLiposomal DoxorubicinOverall Survival AdvantageCancer TreatmentOncologyOvarian Cancer
No additional data available for this publication yet. Check back later!